Acute Myeloid Leukemia Clinical Trials

A listing of 172 Acute Myeloid Leukemia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Acute Myeloid Leukemia

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 172 active clinical trials seeking participants for Acute Myeloid Leukemia research studies. The states with the highest number of trials for Acute Myeloid Leukemia participants are California, Illinois, New York and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

NCT04256317

Recruiting

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 Monotherapy is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidin... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/01/2025

Locations: Keck School of Medicine of USC, Los Angeles, California +25 locations

Keck School of Medicine of USC, Los Angeles, California

UCI Health - Chao Family Comprehensive Cancer Center, Orange, California

Yale University, New Haven, Connecticut

University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida

University of Emory - Winship Cancer Institute, Atlanta, Georgia

Dana-Farber Cancer Institute, Boston, Massachusetts

John Theurer Cancer Center / Hackensack University, Hackensack, New Jersey

Roswell Park Comprehensive Cancer Center, Buffalo, New York

New York University Langone Hospital - Long Island, Mineola, New York

Perlmutter Cancer Center - 34th Street, New York, New York

Icahn School of Medicine at Mount Sinai, New York, New York

Weill Cornell Medical Center, New York, New York

James P. Wilmot Cancer Center, Rochester, New York

Duke University, Durham, North Carolina

Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus, Ohio

Oregon Health and Science University, Portland, Oregon

Oregon Oncology Specialists, Salem, Oregon

Hollings Cancer Center, Charleston, South Carolina

Vanderbilt University Medical Center, Nashville, Tennessee

Baylor Research Institute dba Baylor Scott & White Research Institute, Dallas, Texas

University of Texas Southwestern Medical Center, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

Seattle Cancer Care Alliance, Seattle, Washington

Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin

Eastern Health - Health Sciences Centre, St. John's, Newfoundland and Labrador

Princess Margaret Cancer Centre, Toronto, Ontario

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia

Learn More ›

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560

Recruiting

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D.

Gender:

ALL

Ages:

2 years and above

Trial Updated:

08/01/2025

Locations: City of Hope, Duarte, California +96 locations

City of Hope, Duarte, California

University of California Irvine Medical Center, Orange, California

University of California San Francisco, San Francisco, California

University of Chicago, Chicago, Illinois

St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation, Indianapolis, Indiana

Norton Cancer Institute, Louisville, Kentucky

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Start Midwest, Grand Rapids, Michigan

University of New Mexico, Albuquerque, New Mexico

Montefiore Medical Center, Bronx, New York

Roswell Park Comprehensive Cancer Center, Buffalo, New York

NYU Langone Medical Center, New York, New York

Oregon Health And Science University, Portland, Oregon

Fox Chase Cancer Center, Philadelphia, Pennsylvania

Maine Health, Providence, Rhode Island

University of Tennessee Medical Center, Knoxville, Tennessee

Baylor University Medical Center, Dallas, Texas

Houston Methodist Hospital, Houston, Texas

MD Anderson, Houston, Texas

San Antonio Methodist TX Transplant Physicians Group, San Antonio, Texas

Virginia Commonwealth University, Richmond, Virginia

Swedish Cancer Institute, Seattle, Washington

Medical College of WI at Froedtert, Milwaukee, Wisconsin

Monash Medical Centre, Clayton, Not set

Royal Perth Hospital, Perth, Not set

Gold Coast University Hospital, Southport, Not set

Instituto D Or de Pesquisa e Ensino, Brasilia, Not set

Liga Norte Riograndense Contra O Cancer, Natal, Not set

Ministerio da Saude Instituto Nacional do Cancer, Rio de Janeiro, Not set

Instituto D Or de Pesquisa e Ensino IDOR, Sao Paulo, Not set

Vancouver Coastal Health, Vancouver, British Columbia

Princess Margaret Cancer Centre University Health Network, Toronto, Ontario

Hopital Maisonneuve Rosemont, Montreal, Quebec

Peking University First Hospital, Beijing, Not set

The First Hospital of Jilin University, Changchun, Not set

West China Hospital Si Chuan University, Chengdu, Not set

Nanfang Hospital of Southern Medical Hospital, Guangzhou, Not set

First Affiliated Hospital Medical School of Zhejiang University, Hang Zhou, Not set

Qilu Hospital of Shandong University, Jinan, Not set

The First Affiliated Hospital of NanChang University, Nanchang, Not set

Zhongda Hospital Southeast University, Nanjing, Not set

Institute of Hematology and Blood Diseases Hospital, Tianjin, Not set

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Not set

Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Not set

Henan Cancer Hospital, Zheng Zhou Shi, Not set

Hopital Jean Minjoz, Besancon, Not set

Institut Paoli Calmettes, Marseille, Not set

CHU de Nantes hotel Dieu, Nantes Cedex 1, Not set

Hopital Saint Louis, Paris, Not set

Hopital trousseau- APHP, Paris, Not set

Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie, Pessac, Not set

CHU Lyon Sud, Pierre Benite, Not set

Institut de Cancerologie Strasbourg Europe ICANS, Strasbourg, Not set

Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, Not set

CHU Bretonneau, Tours cedex, Not set

CHRU Nancy Brabois, Vandoeuvre les Nancy, Not set

Gustave Roussy, Villejuif, Not set

Carmel Medical Center, Haifa, Not set

Hadassah University Hospita Ein Kerem, Jerusalem, Not set

Sheba Medical Center, Ramat Gan, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv Yafo, Not set

Kyushu University Hospital, Fukuoka, Not set

Fukushima Medical University Hospital, Fukushima, Not set

Kanazawa University Hospital, Kanazawa, Not set

National Cancer Center Hospital East, Kashiwa, Not set

Kobe City Medical Center General Hospital, Kobe City, Not set

Gunmaken Saiseikai Maebashi Hospital, Maebashi, Not set

Nagoya University Hospital, Nagoya, Not set

Hokkaido University Hospital, Sapporo, Not set

NTT Medical Center Tokyo, Tokyo, Not set

Yamagata University Hospital, Yamagata, Not set

University of Fukui Hospital, Yoshida, Not set

Seoul National University Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Hosp Univ Vall D Hebron, Barcelona, Not set

Hosp Clinic de Barcelona, Barcelona, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp Univ Fund Jimenez Diaz, Madrid, Not set

Clinica Univ. de Navarra, Pamplona, Not set

Hosp Clinico Univ de Salamanca, Salamanca, Not set

Hosp. Virgen Del Rocio, Sevilla, Not set

Hosp. Clinico Univ. de Valencia, Valencia, Not set

China Medical University Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

University Hospital of Wales, Cardiff, Not set

Leeds Teaching Hospitals NHS Trust, Leeds, Not set

The Clatterbridge Cancer Centre, Liverpool, Not set

Guys and St Thomas NHS Foundation Trust, London, Not set

University College London Hospitals, London, Not set

The Christie Nhs Foundation Trust, Manchester, Not set

Oxford University Hospitals NHS Trust, Oxfordshire, Not set

University Hospitals Plymouth NHS Trust, Plymouth, Not set

Conditions: Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia

Learn More ›

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

NCT07046078

Recruiting

This phase II trial tests the safety, side effects, and how well combination chemotherapy with fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin (FLAG-Ida) followed immediately by reduced-intensity total body radiation therapy, called total body irradiation (TBI), and donor hematopoietic cell transplant (HCT) works in treating adults age 60 and older with newly diagnosed adverse-risk acute myeloid leukemia (AML) or other high-grade myeloid cancer. Despite advances in supportive care and the approval of more than 10 new drugs since 2017, the outcomes of older adults with adverse-risk acute myeloid leukemia and other high-grade myeloid cancers remains poor. Most patients are expected to die from their cancer or the consequences of treatment-related side effects. Donor HCT is a very important part of any curative-cancer treatment for these patients. However, while accepted as standard care for decades, this treatment exposes patients to long periods of drug-induced low blood cell counts and the problems associated with low blood counts, like infections and bleeding, which are associated with significant risk of chronic side effects and death. This study will use a different approach to the upfront curative-cancer treatment of older adults with an adverse-risk AML or other high-grade myeloid cancer. This study will use intense chemotherapy followed a few days later by lower-dose TBI and donor HCT. Chemotherapy drugs, such as idarubicin, fludarabine, high-dose cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. G-CSF helps the bone marrow make more white blood cells in patients with low white blood cell count due to cancer treatment. This approach allows effective treatment of cancer cells and overall reduction of the period of low blood cells counts. This decreases the risk for problems associated with low blood counts, such as infection and chronic side effects. Decreasing these are important for older adults who undergo HCT. This treatment strategy may improve treatment outcomes by allowing more patients to successfully undergo donor HCT and reduce the risk of low blood cell counts and the problems associated with low blood counts. Giving chemotherapy followed immediately by reduced-intensity TBI and donor HCT may be safe, tolerable and/or effective in treating adults age 60 and older with newly diagnosed adverse-risk AML or other high-grade myeloid cancer. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/30/2025

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome

Learn More ›

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

NCT06928662

Recruiting

This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell transplant in treating adult patients with cancers of blood-forming cells of the bone marrow (myeloid malignancies) that are at high risk of coming back after treatment (relapse). Cancers eligible for this trial are acute myeloid leukemia (AML), myelodysplastic syndrome... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/30/2025

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Acute Undifferentiated Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome

Learn More ›

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

NCT03471260

Recruiting

This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +3 locations

Conditions: Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome

Learn More ›

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

NCT06287944

Recruiting

This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI) as conditioning treatment for donor stem cell transplant in patients with high-risk acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). Daratumumab is in a class of medications called monoclonal antibodies. It binds to a pr... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/28/2025

Locations: City of Hope Medical Center, Duarte, California

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome

Learn More ›

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

NCT05010772

Recruiting

This phase Ib trial is to find out the side effects and possible benefits of decitabine alone or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating patients with acute myeloid leukemia that is under control (remission). Chemotherapy drugs, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by b... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/28/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Myeloid Leukemia

Learn More ›

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890

Recruiting

To find a recommended dose of HC-7366 to patients with AML. The safety and effects of this drug combination will also be studied.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/25/2025

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Acute Myeloid Leukemia

Learn More ›

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

NCT06138587

Recruiting

The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant. Names of the study therapies involved in this study are: * CIML NK cells intravenous infusion (cellular therapy) * Subcutaneous Inte... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/21/2025

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations

Conditions: Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myeloproliferative Disorders

Learn More ›

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717

Recruiting

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.

Gender:

ALL

Ages:

60 years and below

Trial Updated:

07/21/2025

Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota

Conditions: Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin

Learn More ›

Ziftomenib Maintenance Post Allo-HCT

NCT06440135

Recruiting

The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets and inhibits negative interactions within cancer cells related to AML, when given after allo-HCT, to determine if it improves outcomes following allo-HCT. The name of the study drug involved in this s... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/18/2025

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, NPM1 Mutation, KMT2A Rearrangement

Learn More ›

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

NCT03737955

Recruiting

This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a chemotherapy drug, called ozogamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers a chemotherapy known as calicheamicin to kill them.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/18/2025

Locations: Fred Hutchinson Cancer Center/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Acute Myeloid Leukemia

Learn More ›